Biosynthetic Cross-Linking Reactions

Vancomycin’s bioactive structure arises from enzymatic oxidative cross-linking of a linear heptapeptide precursor. Three cytochrome P450 enzymes (OxyB, OxyA, OxyC) catalyze sequential aryl-ether and carbon-carbon bond formations:

• OxyB : Cross-links residues 4 (Tyr) and 6 (Hpg) via an aryl-ether bond.
• OxyA : Links residues 2 (Hpg) and 4 (Tyr) through a second aryl-ether bond.
• OxyC : Installs a strained carbon-carbon bond between residues 5 (Hpg) and 7 (Dpg), completing the rigid cup-shaped scaffold .

Mechanistic Hydrogen Bonding Interactions

This compound binds the D-Ala-D-Ala terminus of peptidoglycan precursors via five hydrogen bonds:

• Backbone carbonyl of residue 4 (Tyr) ↔ NH of D-Ala.
• Residue 5 (Hpg) NH ↔ D-Ala carbonyl.
• Residue 2 (Hpg) NH ↔ D-Ala carbonyl.
• Residue 6 (Hpg) NH ↔ D-Ala NH.
• Residue 7 (Dpg) NH ↔ D-Ala NH .

This interaction disrupts transglycosylation, weakening bacterial cell walls . Resistance arises when D-Ala-D-Lac replaces D-Ala-D-Ala, eliminating one hydrogen bond and introducing electrostatic repulsion .

Hydrophobic Substituents

Adding hydrophobic groups (e.g., quaternary ammonium moieties) enhances activity against this compound-resistant enterococci (VRE):

Dual-Binding Analogs

Total synthesis enables modifications to the heptapeptide core for dual binding to D-Ala-D-Ala and D-Ala-D-Lac:

• CBP-substituted analogs : MIC reduced from >256 μg/mL to 0.25 μg/mL against VRE .

Degradation and Metabolic Pathways

This compound undergoes enzymatic and environmental degradation:

• In vitro metabolism : Rat liver microsomes catalyze demethylation and hydroxylation .
• Aquatic degradation : Hydrolysis under alkaline conditions cleaves glycosidic bonds, yielding aglycone fragments .

Table 2: Major Degradation Products

Synthetic Conjugation Reactions

This compound’s N-methylleucine residue enables site-specific conjugation:

• Selenocysteine-mediated linking : Attaches antimicrobial peptides (e.g., CRAMP) via selenocysteine handles, enhancing potency against MRSA (MIC: 0.25 μg/mL vs. 2 μg/mL for this compound) .

Structural Analysis via NMR and MS

Nuclear magnetic resonance (NMR) and mass spectrometry (MS) elucidate this compound’s structure:

• 1H-13C HMBC : Confirmed α-L-vancosaminyl-(1→2)-O-β-D-glucosyl linkage .
• CD spectroscopy : Verified 3D structure consistency with reference standards .

Key Findings and Implications

• Biosynthesis : Enzymatic cross-linking by OxyB/OxyA/OxyC is indispensable for bioactivity .
• Resistance Mitigation : Hydrophobic and dual-binding analogs show promise against VRE .
• Degradation : Environmental stability limits ecological impact but necessitates controlled disposal .

This synthesis underscores this compound’s chemical versatility and ongoing efforts to combat resistance through innovative synthetic strategies.

Clinical Applications

FDA-Approved Indications:
Vancomycin is indicated for various infections, including:

• Clostridioides difficile-associated diarrhea
• Staphylococcal infections (including septicemia, skin and soft tissue infections)
• Endocarditis caused by enterococci and staphylococci
• Bone infections and lower respiratory tract infections

Off-Label Uses:
this compound is also utilized in several off-label scenarios:

• Catheter-related infections
• Bacterial meningitis
• Surgical prophylaxis
• Necrotizing skin and soft tissue infections

Research Findings

Recent studies have highlighted the efficacy of this compound in various clinical settings:

• Topical Application in Surgical Site Infections:
  A systematic review indicated that the local application of this compound powder significantly reduces the incidence of surgical site infections (SSIs) following joint arthroplasty. However, it was associated with an increased risk of complications such as delayed healing .
• Pediatric Applications:
  Research has demonstrated this compound's immunomodulatory effects in pediatric patients with inflammatory bowel disease, suggesting its potential role beyond mere antibacterial action .
• Intrawound Use in Spine Surgery:
  A meta-analysis involving 18 studies showed that intrawound application of this compound powder significantly lowers the odds of developing deep infections during spine surgeries compared to standard practices . The odds ratio for deep infections was found to be 0.23, indicating a substantial protective effect.

Data Table: Summary of this compound Applications

バンコマイシンは、細菌の細胞壁合成を阻害することで作用します。 細胞壁前駆体ユニットのD-アラニル-D-アラニン末端に結合し、細胞壁への組み込みを阻止するため、細菌の細胞壁を弱体化させ、細胞溶解と死滅を引き起こします . この機序により、グラム陽性菌に対して非常に有効となっています .

Comparison with Other Glycopeptides and Lipoglycopeptides

Teicoplanin and Dalbavancin

• Teicoplanin : Shares vancomycin’s mechanism but has a longer half-life (70–100 hours vs. This compound’s 4–6 hours) due to lipophilic side chains, enabling once-daily dosing. However, it is less effective against Staphylococcus haemolyticus and some enterococci .
• Dalbavancin : A semi-synthetic lipoglycopeptide with a half-life of 8–12 days, allowing weekly dosing. It demonstrates lower MIC values against MRSA (0.06 µg/mL) compared to this compound (1–2 µg/mL) .

Telavancin and Oritavancin

• Telavancin : A semi-synthetic derivative with dual mechanisms: cell wall inhibition and membrane depolarization. It shows 2–4-fold greater potency than this compound against MRSA (MIC₉₀: 0.5 µg/mL vs. 1 µg/mL) but carries a higher risk of nephrotoxicity .
• Oritavancin : Exhibits prolonged post-antibiotic effects and activity against this compound-resistant enterococci (VRE) due to its ability to dimerize and penetrate biofilms. Its MIC for VRE is 0.25–1 µg/mL, compared to this compound’s >16 µg/mL .

Comparison with Cyclic Lipopeptides: Daptomycin

Unlike this compound, it is bactericidal and effective against this compound-resistant Enterococcus faecium (VREfm). Key differences include:

• Spectrum : Daptomycin covers VRE and Streptococcus bovis, whereas this compound is inactive against VRE.
• Pharmacodynamics : Daptomycin’s AUC/MIC ratio correlates with efficacy, while this compound relies on time above MIC .
• Clinical Outcomes: In trials, daptomycin demonstrated non-inferiority to this compound for MRSA bacteremia but is less effective in pulmonary infections due to surfactant interference .

Comparison with this compound Derivatives

Recent derivatives aim to overcome resistance and enhance efficacy (Table 1):

Clinical Use Comparisons

This compound vs. Gentamicin in Graft Presoaking

For anterior cruciate ligament reconstruction (ACLR), gentamicin and this compound show equivalent infection prevention (0.5% vs. 0.6% incidence). Gentamicin is preferred due to lower cost ($10 vs. $150 per dose) and similar chondrotoxicity profiles .

Nephrotoxicity in Combination Therapy

No significant difference in nephrotoxicity risk was observed between this compound monotherapy and this compound/piperacillin-tazobactam combinations (RR = 1.1, p = 0.073) .

Vancomycin is a glycopeptide antibiotic that plays a crucial role in the treatment of serious infections caused by Gram-positive bacteria, particularly those resistant to other antibiotics. This article delves into its biological activity, mechanisms of action, and recent research findings, including case studies and data tables.

This compound primarily exerts its antibacterial effect by inhibiting cell wall synthesis in bacteria. It binds to the D-alanyl-D-alanine terminus of cell wall precursor units, preventing their incorporation into the growing cell wall. This action leads to cell lysis and death, particularly in rapidly dividing bacteria. Additionally, this compound has been shown to alter the permeability of bacterial cell membranes and inhibit RNA synthesis, further contributing to its antimicrobial effects .

Antibacterial Spectrum

This compound is effective against a broad range of Gram-positive organisms, including:

• Staphylococcus aureus (including MRSA)
• Streptococcus pneumoniae
• Enterococcus faecium (including this compound-resistant strains)
• Clostridium difficile

Despite its effectiveness, this compound has limited activity against Gram-negative bacteria due to its large molecular size and inability to penetrate the outer membrane .

Recent Research Findings

Recent studies have focused on enhancing the efficacy of this compound through various modifications and combinations:

• Novel Derivatives : Research indicates that introducing quaternary ammonium cations into this compound can significantly improve its antibacterial activity. For instance, a derivative known as QAV-a1 showed higher survival rates in infected mice compared to standard this compound at higher doses .
• Conjugation with Cell-Penetrating Peptides (CPPs) : Studies demonstrated that conjugating this compound with CPPs like Tat (47–57) enhances its antimicrobial properties. The cytotoxicity of these conjugates was evaluated, showing varied effects on cell viability at different concentrations .
• Biofilm Activity : this compound's efficacy against biofilms is notably lower than its activity against planktonic cells. Modifications such as dipicolylamine functionalization have been explored to enhance its effectiveness against biofilm-associated infections .

Case Studies

Several case studies illustrate the clinical application of this compound:

• Case Study 1 : A patient with MRSA bacteremia was treated with this compound combined with an aminoglycoside, resulting in a successful outcome. The combination therapy demonstrated enhanced efficacy compared to monotherapy, highlighting the importance of synergistic effects in treatment .
• Case Study 2 : In a pediatric population, the emergence of resistance to this compound was monitored. Despite concerns about resistance patterns, no significant increase was observed over three decades, indicating sustained effectiveness against common pathogens .

Table 1: Efficacy of this compound Against Various Bacterial Strains

Table 2: Comparative Survival Rates in In Vivo Studies